Putting Peptides on the Map
June 8, 2018
Streamlined workflows help scientists plot a course for painless peptide mapping
1 min read
January 2017
Welcome to the January issue. Upfront investigates the relationship between pharma and patients, Donald Trump’s attack on pharma, and chemically functionalized spider silk. In our cover feature, we quiz past contributors for their opinions on 2016 – and ask them what priorities and resolutions the industry should focus on for 2017. NextGen explores modeling in bioprocess development, and in Profession, Rafaat Rahmani explains how he built an award winning global company from the ground up. We also sit down with Dominic Carolan, CEO of the National Institute for Bioprocessing Research and Training (NIBRT).
Pressure Cooker Pricing
February 20, 2017
Marathon Pharmaceuticals’ pricing of Emflaza for Duchenne muscular dystrophy causes controversy
1 min read
Walking the Entrepreneur's Path
January 19, 2017
It’s not easy finding your way “from a garage to a palace.” The journey requires creativity, persistence, humanity – and a little luck.
1 min read
Leading the Way
January 19, 2017
Sitting Down With... Dominic Carolan, CEO, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland.
1 min read
Is the Price Right?
January 19, 2017
Pharma’s business model is increasingly shifting towards expensive specialty medicines, but how much are governments and society willing to pay for these medicines? We need new business model designs and analytics to help measure value.
1 min read
Is Flexibility the Way Forward for Female Leaders?
January 19, 2017
Men continue to dominate upper management positions, but businesses also need the talent and diversity women can bring to drive bottom line results. With a focus on flexibility, things could change for the better.
1 min read
The Bioprocess Model Maker
January 19, 2017
It’s not unusual for companies to struggle with the optimization of bioprocess development. Modeling can certainly help – but what separates a good model from a bad model?
1 min read
Revelations and Resolutions
January 19, 2017
It seems likely that 2016 will go down as one of the most eventful years in modern history, but what did the pharma industry make of it? Here, we quiz a number of past contributors to The Medicine Maker for their opinions on 2016 – and ask them what priorities and resolutions the industry should focus on for 2017.
1 min read
Standing Up for Microcalorimetry
January 19, 2017
Modern microcalorimetry certainly has great potential in biopharma development but, to make the most of any technique, it is important to understand its advantages and limitations.
1 min read
Discovery & Development
Packaging
Facilities & Equipment
Technology & Manufacturing
Regulation & Standards
Business & Trends
Drug Delivery
The Perfect Package
January 19, 2017
Are current guidelines around packaging and product degradation suitable for real market conditions?
1 min read
Biosimilars, Come Fly With Me
January 19, 2017
Let’s follow the tune of the airline industry and cooperate to de-risk investments, optimize costs, and maximize sales.
1 min read
Parents Pass Placebos
January 19, 2017
Is it ethical to use placebo controls in pediatric clinical trials? Most parents say, “yes”
1 min read
Business-in-Brief
January 19, 2017
A patent surprise, authorization denied, and EpiPen’s monopoly compromised... What’s new for pharma in business?
1 min read
Trump Targets Pharma
January 19, 2017
“We’re going to start bidding,” says Trump. Could Medicare price negotiations be on the cards?
1 min read
A Bad Relationship
January 19, 2017
Our infographic highlights the disconnect between patients and drug manufacturers
1 min read
Oh, What a Wonderful Web We Weave
January 19, 2017
Could chemically functionalized spider silk be used for innovative drug delivery?
1 min read
Relating the Geno to the Pheno
January 19, 2017
Health data analytics seek to unravel the biology behind Alzheimer’s and Schizophrenia
1 min read
Failure to Engage
January 19, 2017
Could public health suffer if the pharma industry doesn’t learn how to win back trust?
1 min read
